Suppr超能文献

抗高血压药物抵抗作为肾动脉狭窄的预测指标:两种药物治疗方案的比较

Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens.

作者信息

van Jaarsveld B C, Krijnen P, Derkx F H, Deinum J, Woittiez A J, Postma C T, Schalekamp M A

机构信息

Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.

出版信息

J Hum Hypertens. 2001 Oct;15(10):669-76. doi: 10.1038/sj.jhh.1001258.

Abstract

BACKGROUND

Renal artery stenosis is among the most common curable causes of hypertension. The definitive diagnosis is made by renal angiography, an invasive and costly procedure. The prevalence of renal artery stenosis is less than 1% in non-selected hypertensive patients but is higher when hypertension is resistant to drugs.

OBJECTIVE

To study the usefulness of standardised two-drug regimens for identifying drug-resistant hypertension as a predictor of renal artery stenosis.

DESIGN AND SETTING

Prospective cohort study carried out in 26 hospitals in The Netherlands.

PATIENTS

Patients had been referred for analysis of possible secondary hypertension or because hypertension was difficult to treat. Patients < or =40 years of age were assigned to either amlodipine 10 mg or enalapril 20 mg, and patients >40 years to either amlodipine 10 mg combined with atenolol 50 mg or to enalapril 20 mg combined with hydrochlorothiazide 25 mg. Renal angiography was performed: (1) if hypertension was drug-resistant, ie if diastolic pressure remained > or =95 mm Hg at three visits 1-3 weeks apart or an extra drug was required, and/or (2) if serum creatinine rose by > or =20 micromol/L (> or =0.23 mg/dL) during ACE inhibitor treatment.

RESULTS

Of the 1106 patients with complete follow-up, 1022 had been assigned to either the amlodipine- or enalapril-based regimens, 772 by randomisation. Drug-resistant hypertension, as defined above, was identified in 41% of the patients, and 20% of these had renal artery stenosis. Renal function impairment was observed in 8% of the patients on ACE inhibitor, and this was associated with a 46% prevalence of renal artery stenosis. In the randomised patients, the prevalence of renal artery stenosis did not differ between the amlodipine- and enalapril-based regimens.

CONCLUSIONS

In the diagnostic work-up for renovascular hypertension the use of standardised medication regimens of maximally two drugs, to identify patients with drug-resistant hypertension, is a rational first step to increase the a priori chance of renal artery stenosis. Amlodipine- or enalapril-based regimens are equally effective for this purpose.

摘要

背景

肾动脉狭窄是高血压最常见的可治愈病因之一。确诊需通过肾血管造影,这是一种有创且昂贵的检查方法。在未经挑选的高血压患者中,肾动脉狭窄的患病率低于1%,但在难治性高血压患者中患病率更高。

目的

研究标准化双药方案在识别难治性高血压作为肾动脉狭窄预测指标方面的作用。

设计与地点

在荷兰26家医院开展的前瞻性队列研究。

患者

患者因可能的继发性高血压或高血压难以治疗而被转诊。年龄≤40岁的患者被分配服用氨氯地平10毫克或依那普利20毫克,年龄>40岁的患者被分配服用氨氯地平10毫克联合阿替洛尔50毫克或依那普利20毫克联合氢氯噻嗪25毫克。进行肾血管造影:(1)如果高血压为难治性,即相隔1 - 3周的三次就诊时舒张压均≥95毫米汞柱或需要加用另一种药物,和/或(2)如果在使用血管紧张素转换酶抑制剂治疗期间血清肌酐升高≥20微摩尔/升(≥0.23毫克/分升)。

结果

在1106例完成随访的患者中,1022例被分配到基于氨氯地平或依那普利的方案,其中772例通过随机分组。按照上述定义,41%的患者被识别为难治性高血压,其中20%患有肾动脉狭窄。在服用血管紧张素转换酶抑制剂的患者中,8%出现肾功能损害,这与肾动脉狭窄患病率46%相关。在随机分组的患者中,基于氨氯地平与基于依那普利的方案中肾动脉狭窄的患病率无差异。

结论

在肾血管性高血压的诊断检查中,使用最多两种药物的标准化用药方案来识别难治性高血压患者,是提高肾动脉狭窄先验概率的合理第一步。基于氨氯地平或依那普利的方案在这方面同样有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验